November 07, 2013 at 06:38 AM EST
Coronado Biosciences Announces Independent Data Monitoring Committee Recommends Discontinuing Falk Phase 2 Trial of TSO in Crohn's Disease
Coronado Biosciences (NASDAQ: CNDO ) today announced that it has been informed by Dr. Falk Pharma GmbH (Falk), its development partner, that an Independent Data Monitoring Committee (IDMC) has conducted a second interim analysis of clinical data from approximately 240 patients who have completed 12 weeks of treatment in
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here